Clinical Trials Arena lists five of the most popular tweets on cardiology in February 2022 based on data from GlobalData’s Pharmaceuticals Influencer Platform.
The top tweets are based on total engagements (likes and retweets) received on tweets from more than 150 cardiology experts tracked by GlobalData’s Pharmaceuticals Influencer platform during February 2022.
The most popular tweets on cardiology in February 2022: Top five
1. Philippe Pibarot’s tweet on the effectiveness of cardiac surgery in improving survival in patients with transcatheter aortic valve implantation-infective endocarditis (TAVI-IE)
Philippe Pibarot, a clinical scientist and professor, tweeted on research showing that surgical intervention in patients with infective endocarditis after transcatheter aortic valve implantation (TAVI-IE) did not improve survival or one-year mortality as compared to medical therapy. In the international registry, a majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery combined with antibiotics did not show improvement in all-cause in-hospital or one-year mortality in patients.
The research paper further detailed that the high death rates of patients with TAVI-IE were related to their individual characteristics, IE-related problems, and pathogen. About 584 patients were investigated, which included 19% or 111 patients treated with cardiac surgery and antibiotics (IE-CS) and 81% or 473 patients treated with antibiotics alone (IE-AB).
Username: Philippe Pibarot
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Twitter handle: @PPibarot
2. Pradeep Natarajan’s tweet on the use of evidence-based cardiovascular preventative therapies in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD)
Pradeep Natarajan, director of preventative cardiology at the Massachusetts General Hospital, shared a study on the underutilisation of evidence-based therapies for cardiovascular risk reduction among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) in the US.
As many as 324,706 patients were evaluated in the study across 12 health systems, and it was found that less than one in 20 patients were given all three evidence-based therapies, including high-intensity statin, either an angiotensin-converting enzyme inhibitor (AECI) or angiotensin-receptor blocker (ARB), and either a sodium-glucose cotransporter-2 inhibitors (SGLT2I) and/or a glucagon-like peptide-1 receptor agonist (GLP-1RA). The findings suggested that multidimensional interventions are required to overcome the barriers to using evidence-based therapies and encourage their best possible use.
Username: Pradeep Natarajan
Twitter handle: @pnatarajanmd
3. Raviele Antonio’s tweet on the corelation between excess daytime sleepiness and increased cardiovascular risk
Raviele Antonio, a cardiologist and president of Alfa – Alliance to Fight Atrial Fibrillation, based in Italy, shared an infographic on plausible mechanisms on how excessive daytime sleepiness can increase the risk of cardiovascular mortality. According to a theoretical framework presented by the researchers, excessive daytime sleepiness is linked to dysbiosis of the gut microbiome, adipose dysfunction, and predispositions/epigenetic changes, which can directly contribute to enhanced cardiovascular risk in individuals reporting excessive sleepiness during the day.
The research further highlighted that sleepiness was measured by the frequency at which individuals felt overly sleepy within a month.
Username: Raviele Antonio
Twitter handle: @drraviele
4. Dr Deepak L Bhatt’s tweet on diagnosing and treating acute coronary syndromes (ACS)
Dr Deepak L Bhatt, a cardiologist at Brigham and Women’s Hospital and VA Boston Healthcare, shared a study on diagnosing and treating ACS, which encompasses a range of disorders characterised by a sudden reduction in the blood flow to the heart. The disorders include non-STEMI (NSTEMI), ST-segment elevation myocardial infarction (STEMI), and unstable angina. The study highlighted that chest discomfort at rest is the most common symptom of ACS, affecting approximately 79% of men and 74% of women with ACS. More than seven million individuals are diagnosed with ACS every year worldwide, among who more than one million are required to be hospitalised in the US alone.
The study further noted that electrocardiography should be performed within ten minutes of observing possible ACS in the patients, which can distinguish between STEMI and non–ST-segment elevation ACS (NSTE-ACS). For people with STEMI, coronary catheterisation, and percutaneous coronary intervention (PCI) within two hours of observing possible ACS reduced mortality. The research also highlighted the importance of quick invasive coronary angiography followed by percutaneous or surgical revascularisation within the next 24 to 48 hours, which helped in reducing the risk of death from 6.5% to 4.9% in high-risk patients with NSTE-ACS and no contraindications.
Username: Dr. Deepak L. Bhatt
Twitter handle: @DLBHATTMD
5. Roger Blumenthal’s tweet on the association of Lp(a) and coronary artery calcification (CAC) with atherosclerotic cardiovascular disease (ASCVD)
Roger Blumenthal, director of the Ciccarone Centre for Prevention of Cardiovascular Disease, shared an article on the joint association of lipoprotein(a) [Lp(a)] and CAC with increased risk of atherosclerotic cardiovascular disease (ASCVD). Researchers observed 476 incident major ASCVD events during 13.2 years of follow-up among asymptomatic participants of the Multi-Ethnic Study of Atherosclerosis (MESA). They found that both Lp(a) and CAC were independently associated with ASCVD risk of death, fatal and non-fatal myocardial infarction (MI), and stroke after adjusting other risk factors such as family history of MI and each other.
The study also noted that no difference was observed in incident ASCVD for people falling within CAC score category zero to less than 100 when the Lp(a) was more than or equal to 50 mg/dL, the level at which Lp(a) is considered to be a risk-enhancing factor. The research also suggested that both Lp(a) and CAC may be used alongside to take primary prevention therapy decisions.
Username: Roger Blumenthal
Twitter handle: @rblument1
Likes: 24 Retweets: 6